Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Drug Delivery Business

Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes

Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes.
Zacks Investment Research on MSN

Dexcom reports positive CONNECT data for non-insulin diabetes

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...

Dexcom bolsters evidence for glucose sensors for Type 2 diabetes

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
Fierce Biotech

ADA: Dexcom CGM shows benefit in non-insulin diabetes patients

A Dexcom continuous glucose monitor (CGM) helped adults with type 2 diabetes not using insulin improve blood sugar control in ...